Quick Answer
Kiniksa Pharmaceuticals International, plc reported Total Revenue of $677.56 million for fiscal year 2025.
Kiniksa Pharmaceuticals International, plc Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $677.56M | +60.1% |
| 2024 | $423.24M | +56.6% |
| 2023 | $270.26M | +22.7% |
| 2022 | $220.18M | +471.2% |
| 2021 | $38.54M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $180.85M | +61.2% | +15.3% |
| June 30, 2025 | $156.80M | +44.3% | +13.8% |
| March 31, 2025 | $137.78M | +72.5% | +22.8% |
| September 30, 2024 | $112.21M | +67.4% | +3.3% |
| June 30, 2024 | $108.63M | +52.0% | +36.0% |
| March 31, 2024 | $79.86M | +65.2% | +19.1% |
| September 30, 2023 | $67.05M | -32.4% | -6.2% |
| June 30, 2023 | $71.47M | +165.0% | +47.8% |
- Kiniksa Pharmaceuticals International, plc showed an increase of +60.1% in Total Revenue compared to the prior fiscal year.
- Over the 2021–2025 period, Kiniksa Pharmaceuticals International, plc’s total revenue has grown by 1657.9% (from $38.54 million to $677.56 million).
- The most recent figure is from Kiniksa Pharmaceuticals International, plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: